You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR COMMIT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for COMMIT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000895 ↗ A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection. HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
NCT00074737 ↗ Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Completed Eleos, Inc. Phase 2 2004-04-01 The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine (Ara-C). Cenersen sodium is a drug that is designed to block the effects of a protein called p53. Laboratory evidence shows that blocking p53 will make many types of cancer, including acute myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics while making normal tissues more resistant to the toxic effects of these agents.
NCT00132899 ↗ COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) Completed Schering-Plough Phase 3 2005-12-01 The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy.
NCT00132899 ↗ COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) Completed University of Western Ontario, Canada Phase 3 2005-12-01 The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for COMMIT

Condition Name

Condition Name for COMMIT
Intervention Trials
Diabetes Mellitus 12
Crohn's Disease 2
Depression 2
Tobacco Use Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for COMMIT
Intervention Trials
Diabetes Mellitus 13
Disease 3
Tobacco Use Disorder 3
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for COMMIT

Trials by Country

Trials by Country for COMMIT
Location Trials
United States 272
United Kingdom 7
South Africa 6
Brazil 5
Mexico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for COMMIT
Location Trials
Texas 12
Florida 12
California 12
South Carolina 11
Pennsylvania 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for COMMIT

Clinical Trial Phase

Clinical Trial Phase for COMMIT
Clinical Trial Phase Trials
Phase 4 9
Phase 3 12
Phase 2 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for COMMIT
Clinical Trial Phase Trials
Completed 26
Recruiting 5
Terminated 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for COMMIT

Sponsor Name

Sponsor Name for COMMIT
Sponsor Trials
Takeda 13
National Cancer Institute (NCI) 3
National Institute on Drug Abuse (NIDA) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for COMMIT
Sponsor Trials
Other 37
Industry 25
NIH 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.